Zscaler Reports Robust Third-Quarter Growth with AI-Driven Advances

Published 20 hours agoZS

Zscaler Reports Robust Third-Quarter Growth with AI-Driven Advances

Zscaler, Inc. delivered impressive third-quarter results for the fiscal year 2024, showcasing substantial growth and notable strategic initiatives. The company reported a 32% year-over-year increase in revenue, totaling $553.2 million. Additionally, adjusted earnings per share of $0.88 surpassed analyst expectations of $0.65. Zscaler's calculated billings also saw a rise of 30%, reaching $628.0 million in this quarter. These figures underline Zscaler's strong financial performance amidst a growing demand for cybersecurity solutions.

In terms of strategic movements, Zscaler made noteworthy acquisitions to bolster its AI capabilities and reinforce its market position. The acquisition of Avalor Technologies in March 2024 aimed to integrate Avalor's Data Fabric for Security with Zscaler's existing data infrastructure. Following this, Zscaler acquired Airgap Networks in April 2024, enhancing its Zero Trust security approach by combining Airgap's agentless segmentation technology with its own offerings. Furthermore, Zscaler announced AI innovations like the ZDX Copilot for IT operations and security insights, alongside launching GenAI App Security to protect AI application usage from data leaks.

Recognized for its leadership in the cybersecurity domain, Zscaler was named a Leader in both the Forrester Wave and Gartner Magic Quadrant reports for 2024, highlighting its continued excellence in Security Service Edge solutions. Looking ahead, Zscaler has projected Q4 revenue guidance of $565 million to $567 million and expects full fiscal 2024 revenue between $2.140 billion and $2.142 billion. These strategic and technological advancements, along with market recognition, reflect Zscaler's ongoing commitment to innovation within the cybersecurity landscape.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Palantir's Stock Surges on AI and Defense Contracts

Palantir's Stock Surges on AI and Defense Contracts

8 minutes agoPLTR

Palantir Technologies has seen a notable rise in its stock value, bolstered by substantial government contracts and advancements in artificial intelligence capabilities. This momentum was significantly propelled by NATO's recent acquisition of Palantir's Maven Smart System, an AI-driven military tool designed to improve battlefield data analysis. This development highlights the increasing role Palantir plays in cutting-edge defense technology. Earlier this month, Palantir reported strong financial metrics for Q1 2025, with revenue climbing 39% year-over-year to $884 million and net income more than doubling to $214 million. Based on these strong results, the company increased its annual revenue growth forecast to 36%, surpassing Wall Street's expectations, as noted by ft.com. Additionally, in March, Palantir secured a four-year, $400 million contract extension with the U.S. Army for its Vantage program, further cementing its pivotal role in military applications. Palantir's burgeoning AI platform is also making strides in the commercial sector, contributing to a 55% increase in U.S. commercial revenue in Q2 2024. The company’s stock is currently trading at $127.02, reflecting steady investor confidence. The stock's performance is indicative of Palantir's strategic focus on AI and defense, which has driven both its financial performance and stock market success.

Wells Fargo Offloads $4.4 Billion Rail Leasing Business

Wells Fargo Offloads $4.4 Billion Rail Leasing Business

38 minutes agoGATX

Wells Fargo has reached an agreement to sell its rail equipment leasing business, valued at $4.4 billion, to a newly established joint venture between GATX Corporation and Brookfield Infrastructure. This move will transfer a substantial portfolio that includes about 105,000 railcars, 23,000 finance lease railcars, and 440 locomotives, as reported by Reuters. In the new joint structure, GATX will initially hold a 30% stake while Brookfield Infrastructure will possess 70%. GATX has the option to gradually acquire complete ownership. They will also take control of managing all commercial and operational aspects of the rail assets, ensuring a seamless transition and continuation of services. Wells Fargo sees this transaction as a step towards refining its business focus on core operations, with the deal expected to conclude by the first quarter of 2026. This strategic sale is not anticipated to have a major impact on Wells Fargo's financial metrics, underscoring the bank's intent to enhance operational efficiency.

Gilead Pledges HIV Drug Access Amidst Uncertain Funding

Gilead Pledges HIV Drug Access Amidst Uncertain Funding

1 hours agoGILD

Gilead Sciences is moving forward with plans to supply its innovative HIV prevention injection, lenacapavir, to low-income countries, even in the face of potential funding uncertainties. This promise hinges on securing a U.S. FDA approval by June 19, 2025, Reuters reported. The drug has shown nearly 100% efficacy in trials, positioning it as a potential game changer in the fight against HIV. Central to Gilead's strategy is offering lenacapavir at cost for the first two to three years and partnering with six generic manufacturers to make affordable versions available in 120 low- and middle-income countries. The initial focus will be on reaching 2 million people in 18 low-income countries, working alongside initiatives like PEPFAR and the Global Fund, according to Gilead’s official statements. However, the plan faces potential hurdles due to recent cuts in U.S. funding for HIV programs, raising concerns about its implementation. Despite these challenges, the broader vision remains supported by global organizations such as the Gates Foundation and Elton John AIDS Foundation, indicating that international cooperation could maintain momentum regardless of U.S. financial backing. Notably, the market expectation is strong, with projected U.S. sales of lenacapavir hitting $1 billion annually by 2026. Advocates worry about the potential spike in HIV infections if preventive measures are disrupted, underscoring the importance of maintaining support and funding.

Deutsche Bank Reaffirms Buy Rating on UnitedHealth Amid Positive Earnings

Deutsche Bank Reaffirms Buy Rating on UnitedHealth Amid Positive Earnings

Deutsche Bank has reaffirmed its "Buy" rating on UnitedHealth Group, setting a price target at $625. This stance is fueled by what Deutsche Bank views as the company's attractive valuation. Positive earnings performance has played a significant role in bolstering this outlook, with UnitedHealth recently surpassing earnings expectations, further strengthening investors' confidence, as noted by Investing.com. Adding to the optimism, a recent legal development could potentially benefit UnitedHealth. A special master has recommended dismissing a Department of Justice lawsuit that alleged the company overbilled Medicare. This recommendation could remove a looming financial uncertainty for UnitedHealth, thus enhancing its financial stability. Beyond Deutsche Bank, other analysts are also expressing confidence in UnitedHealth. Firms like Piper Sandler and Bernstein SocGen Group have maintained positive ratings for the insurance giant, which suggests strong analyst consensus regarding the company's solid prospects moving forward.